Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Double-blind, Double-dummy, Randomized, Active-controlled Phase III Study to Evaluate the Efficacy and Safety of Xyzal® 5mg od vs Zyrtec® 10mg od in Subjects Aged 15 Years and Above With Dermatitis and Eczema

NCT00375713 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00375713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00375713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Double-blind, Double-dummy, Randomized, Active-controlled Phase III Study to Evaluate the Efficacy and Safety of Xyzal® 5mg od vs Zyrtec® 10mg od in Subjects Aged 15 Years and Above With Dermatitis and Eczema
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2005
Completion date
May 31, 2006
Enrollment
466 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis, eczema